Faruqi & Faruqi Encourages Soleno Investors to Reach Out

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 15 hours ago

0mins

SLNO-3.84%

Should l Buy SLNO?

Source: PRnewswire

Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Soleno Therapeutics, particularly for investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, highlighting the firm's commitment to investor rights.
Investor Contact Information: Investors who suffered losses are encouraged by Faruq & Faruq's Securities Litigation Partner Josh Wilson to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), ensuring they receive timely legal support.
Class Action Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the urgency and significance of the legal process.
Potential Impact Assessment: This investigation may negatively affect Soleno's stock price and corporate reputation, prompting investors to stay informed on developments to protect their interests.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SLNO

Wall Street analysts forecast SLNO stock price to rise

8 Analyst Rating

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 40.610

Low

75.00

Averages

110.50

High

125.00

Current: 40.610

Low

75.00

Averages

110.50

High

125.00

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$120 -> $100

2026-03-04

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$120 -> $100

AI Analysis

2026-03-04

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Soleno Therapeutics to $100 from $120 and keeps a Buy rating on the shares post the Q4 report. The firm says the company has a solid commercial outlook. The analyst modulated the firm's peak market share expectations for Vykat in the U.S. to 20% of the total Prader-Willi syndrome market.

Wells Fargo

Overweight

downgrade

$114 -> $110

2026-02-27

Reason

Wells Fargo

Price Target

$114 -> $110

2026-02-27

downgrade

Overweight

Reason

Wells Fargo lowered the firm's price target on Soleno Therapeutics to $110 from $114 and keeps an Overweight rating on the shares. While management's commentary on building out a pipeline plus LCM for Vykat XR and the CFO's retirement may remove some investors' near-term takeout thesis, the firm notes shares remain cheap relative to expected FY26 revenue and cash flow. Wells is a buyer at these levels.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SLNO

Unlock Now

About SLNO

Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Soleno Therapeutics Faces Securities Class Action Lawsuit

3 hours agoGlobenewswire

Filing Deadline: ClaimsFiler reminds Soleno Therapeutics investors that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26 and November 4, 2025, highlighting the legal risks facing investors.
Legal Allegations: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding undisclosed safety concerns related to DCCR, the company's only commercial product.
Safety Concerns: The lawsuit claims that the Phase 3 clinical trial for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and commercial viability.
Commercial Viability Risks: The undisclosed safety risks raise significant concerns about DCCR's commercial viability, potentially leading to higher patient discontinuation rates, reluctance from prescribers, and possible legal and reputational fallout, exacerbating investor anxiety.

Class Action Reminder for Soleno Therapeutics Shareholders

3 hours agoGlobenewswire

Lawsuit Background: Robbins LLP reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that a class action has been filed, alleging the company failed to disclose safety concerns regarding the DCCR clinical trial, resulting in investor losses.
Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during its Phase 3 clinical trial, including fluid retention in participants, which materially decreased the drug's commercial viability and increased risks of patient discontinuation and prescriber reluctance.
Stock Price Volatility: Following the August 15, 2025, report by Scorpion Capital revealing clinical trial issues, Soleno's stock price dropped nearly 12% over two days; additionally, after a patient death linked to DCCR was reported on September 10, 2025, the stock fell nearly 19% in two days.
Financial Impact: On November 4, 2025, Soleno reported its Q3 financial results, with CEO Bhatnagar noting that the Scorpion report disrupted DCCR's launch trajectory, leading to fewer patient start forms and increased discontinuations, causing the stock to plummet from nearly $64 on November 4 to about $47 on November 5, a one-day decline of approximately 27%.

Soleno Therapeutics Class Action Notice Issued

8 hours agoGlobenewswire

Class Action Initiation: Soleno Therapeutics faces a class action lawsuit for failing to disclose safety concerns related to its DCCR drug, with investors able to apply as lead plaintiffs by May 5, 2026, potentially impacting the company's reputation and stock price.
Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety risks during DCCR's clinical trials, raising investor doubts about its commercial viability and potentially leading to greater legal liabilities.
Stock Price Volatility: Following the release of a critical report, Soleno's stock price plummeted nearly 27% within days, reflecting market concerns over the safety and commercial prospects of its product, which may affect future fundraising efforts.
Legal Representation Strength: Robbins Geller, representing the plaintiffs, has recovered $8.4 billion for investors over the past five years, showcasing its strong track record in securities fraud cases, which may enhance the likelihood of success in this lawsuit.